Filing Flows › Comparisons › BDPT vs LYEL
Bioadaptives vs Lyell Immunopharma: BDPT and LYEL compared
Bioadaptives is the larger company: $5K of revenue in its latest quarter (Q2 2026) against $3K for Lyell Immunopharma (Q3 2026). Bioadaptives is growing faster (+55% against -80% a year earlier).
Where the money goes: BDPT and LYEL
Bioadaptives (BDPT) · Q2 2026
Bioadaptives, Q2 2026: revenue $5K (+55% year over year), net earnings $150K, operating cash flow −$44K. The chart follows the revenue to costs, profit and cash.
Lyell Immunopharma (LYEL) · Q3 2026
Lyell Immunopharma, Q3 2026: revenue $3K (-80% year over year), net loss $45.5M, operating cash flow −$34.6M. The chart follows the revenue to costs, profit and cash.
| Bioadaptives (BDPT) | Lyell Immunopharma (LYEL) | |
|---|---|---|
| Latest quarter | Q2 2026 | Q3 2026 |
| Revenue | $5K | $3K |
| Revenue growth, Y/Y | +55% | -80% |
| Operating margin | n/m | n/m |
| Net earnings | $150K | −$45.5M |
| Operating cash flow | −$44K | −$34.6M |
Questions
Which is bigger, Bioadaptives or Lyell Immunopharma?
Bioadaptives is the larger company: $5K of revenue in its latest quarter (Q2 2026) against $3K for Lyell Immunopharma (Q3 2026).
Is Bioadaptives or Lyell Immunopharma growing faster?
Bioadaptives is growing faster (+55% against -80% a year earlier).
More: Bioadaptives earnings · how Bioadaptives makes money · Lyell Immunopharma earnings · how Lyell Immunopharma makes money
From the companies' latest 10-Q, 10-K or earnings release (10-Q filed Aug 19, 2026; 10-Q filed Nov 4, 2026). Fiscal quarters can end on different dates. Not investment advice.